Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Apollomics (NASDAQ: APLM) has entered into a development and commercialization agreement with LaunXP for vebreltinib in combination with EGFR inhibitor for non-small cell lung cancer (NSCLC) treatment in Asia, excluding mainland China, Hong Kong, and Macau.
The deal includes $10 million in upfront payments to Apollomics within 60 days, potential pre-commercial milestones up to $50 million, and royalties on net product sales. LaunXP will lead the development of the combination therapy in their designated territory.
Vebreltinib, Apollomics' proprietary c-Met inhibitor, combined with EGFR inhibitor therapy aims to transform NSCLC treatment by potentially delaying resistance mutations and improving patient outcomes.
Apollomics (NASDAQ: APLM) ha stipulato un accordo di sviluppo e commercializzazione con LaunXP per vebreltinib in combinazione con un inibitore dell'EGFR per il trattamento del cancro polmonare non a piccole cellule (NSCLC) in Asia, escluse Cina continentale, Hong Kong e Macao.
L'accordo include 10 milioni di dollari in pagamenti iniziali a Apollomics entro 60 giorni, potenziali traguardi pre-commerciali fino a 50 milioni di dollari e royalties sulle vendite nette del prodotto. LaunXP guiderà lo sviluppo della terapia combinata nel proprio territorio designato.
Vebreltinib, l'inibitore c-Met proprietario di Apollomics, combinato con la terapia inibitrice dell'EGFR, mira a trasformare il trattamento del NSCLC ritardando potenzialmente le mutazioni di resistenza e migliorando i risultati per i pazienti.
Apollomics (NASDAQ: APLM) ha firmado un acuerdo de desarrollo y comercialización con LaunXP para vebreltinib en combinación con un inhibidor de EGFR para el tratamiento del cáncer de pulmón no microcítico (NSCLC) en Asia, excluyendo China continental, Hong Kong y Macao.
El acuerdo incluye 10 millones de dólares en pagos iniciales a Apollomics dentro de los 60 días, posibles hitos pre-comerciales de hasta 50 millones de dólares y regalías sobre las ventas netas del producto. LaunXP liderará el desarrollo de la terapia combinada en su territorio designado.
Vebreltinib, el inhibidor c-Met propietario de Apollomics, combinado con la terapia inhibidora de EGFR, tiene como objetivo transformar el tratamiento del NSCLC al retrasar potencialmente las mutaciones de resistencia y mejorar los resultados para los pacientes.
Apollomics (NASDAQ: APLM)는 LaunXP와 비소세포 폐암(NSCLC) 치료를 위한 EGFR 억제제와의 병용 요법으로 vebreltinib의 개발 및 상용화 계약을 체결했습니다. 이 계약은 중국 본토, 홍콩 및 마카오를 제외한 아시아에서 진행됩니다.
계약에는 1천만 달러의 선불금이 Apollomics에 60일 이내에 지급되며, 최대 5천만 달러의 상업적 이정표와 순 제품 판매에 대한 로열티가 포함됩니다. LaunXP는 지정된 지역 내에서 병용 요법 개발을 주도할 것입니다.
Apollomics의 독점 c-Met 억제제인 vebreltinib은 EGFR 억제제 요법과 결합하여 NSCLC 치료를 혁신하고 저항 돌연변이를 지연시키며 환자의 결과를 개선하는 것을 목표로 합니다.
Apollomics (NASDAQ: APLM) a conclu un accord de développement et de commercialisation avec LaunXP pour le vebreltinib en combinaison avec un inhibiteur de l'EGFR pour le traitement du cancer du poumon non à petites cellules (NSCLC) en Asie, à l'exclusion de la Chine continentale, de Hong Kong et de Macao.
L'accord comprend 10 millions de dollars de paiements initiaux à Apollomics dans les 60 jours, des jalons pré-commerciaux pouvant atteindre 50 millions de dollars et des redevances sur les ventes nettes du produit. LaunXP dirigera le développement de la thérapie combinée dans son territoire désigné.
Le vebreltinib, inhibiteur c-Met propriétaire d'Apollomics, combiné à la thérapie inhibitrice de l'EGFR, vise à transformer le traitement du NSCLC en retardant potentiellement les mutations de résistance et en améliorant les résultats pour les patients.
Apollomics (NASDAQ: APLM) hat eine Entwicklungs- und Commercialisierungsvereinbarung mit LaunXP für vebreltinib in Kombination mit einem EGFR-Inhibitor zur Behandlung von nicht-kleinzelligem Lungenkrebs (NSCLC) in Asien, mit Ausnahme von Festlandchina, Hongkong und Macau, getroffen.
Das Geschäft umfasst 10 Millionen Dollar an Vorauszahlungen an Apollomics innerhalb von 60 Tagen, potenzielle vor-kommerzielle Meilensteine von bis zu 50 Millionen Dollar und Lizenzgebühren auf Nettoumsätze des Produkts. LaunXP wird die Entwicklung der Kombinationstherapie in ihrem zugewiesenen Gebiet leiten.
Vebreltinib, Apollomics' proprietärer c-Met-Inhibitor, in Kombination mit der EGFR-Inhibition zielt darauf ab, die Behandlung von NSCLC zu revolutionieren, indem mögliche Resistenzmutationen verzögert und die Ergebnisse für die Patienten verbessert werden.
- Secured $10M upfront payment and up to $50M in milestone payments
- Expansion into Asian markets (excluding China, Hong Kong, Macau)
- Development costs in territory transferred to partner LaunXP
- Potential ongoing revenue through royalty payments
- Giving up development and commercialization rights in significant Asian markets
Insights
Apollomics securing a
The strategic partnership with LaunXP creates a pathway to commercialize vebreltinib in combination with EGFR inhibitors for NSCLC in Asian markets without Apollomics bearing the full development costs. This arrangement is particularly valuable as EGFR inhibitors represent a cornerstone therapy for NSCLC, and resistance development remains a critical challenge.
The scientific rationale is compelling - c-Met activation is a known resistance mechanism to EGFR inhibitors. By combining vebreltinib with an EGFR inhibitor, the companies aim to delay or prevent resistance emergence, potentially extending treatment durability for patients. The deal structure allows Apollomics to maintain rights in major markets while monetizing Asian territories.
With LaunXP taking primary responsibility for regional development, Apollomics can focus resources on other programs while still benefiting from milestone payments and potential royalty streams if successful. This represents efficient capital allocation and risk management for a small biotech company while preserving significant upside.
This licensing deal demonstrates exceptional value creation for Apollomics. The
The deal structure intelligently segments geographies, allowing Apollomics to maintain full rights in Western markets and mainland China while monetizing other Asian territories. The
LaunXP assumes development costs and risks in their territories, effectively providing non-dilutive R&D funding while Apollomics retains strategic optionality for the asset globally. The partnership validates vebreltinib's potential by attracting a partner willing to make substantial upfront commitments.
The combination strategy with EGFR inhibitors positions vebreltinib to potentially address a significant unmet need in NSCLC treatment - resistance development. If successful, this approach could establish the combination as a new standard of care, significantly expanding market opportunity beyond what either agent could achieve alone, while serving patients with improved clinical outcomes.
- LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer (“NSCLC”)
- Apollomics to receive upfront payments of
$10 million , and is eligible for pre-commercial milestones up to$50 million , and royalties on net product sales
FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and LaunXP International Co., Ltd., an affiliate of LaunXP Biomedical Co., Ltd. (TWO: 6876) (“LaunXP”), announced today that the parties have entered into an agreement for the development and commercialization in Asia (excluding mainland China, Hong Kong and Macau) (the “LaunXP Territory”) of vebreltinib, Apollomics’ proprietary c-Met inhibitor, in combination with an EGFR inhibitor (“EGFRi”) for the treatment of NSCLC. The EGFRi class of targeted kinase inhibitors is currently a foundational targeted therapy for the treatment of NSCLC and other tumor types.
“We are delighted to partner with LaunXP, who share our vision for the commercial opportunity for vebreltinib. EGFRi is currently the frontline treatment for many patients with NSCLC, and combining it with our c-Met inhibitor vebreltinib is expected to transform the standard of care,” said Dr. Guo-Liang Yu, CEO of Apollomics. “We believe that LaunXP can advance this development program rapidly in this patient population, bringing us closer to potentially improving outcomes for many patients with NSCLC. We will continue to seek opportunities to maximize the global opportunity for vebreltinib, both as a single agent and in combination approaches for the treatment of cancers.”
“We are thrilled to announce this collaboration with Apollomics. We believe the preclinical and clinical data supporting the combination of a c-Met inhibitor with an EGFRi is compelling,” said Dr. Chiu-Heng Chen, Chairman and President of LaunXP. “By delaying the emergence of mutations which cause EGFRi resistance, we hope to demonstrate clinically that better patient outcomes can be achieved.”
Under the terms of the agreement, Apollomics is to receive upfront payments totaling
About Vebreltinib
Vebreltinib is a potent, small molecule, orally bioavailable and highly selective c-MET inhibitor. It works by inhibiting the aberrant activation of the HGF/c-MET axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies such as osimertinib. By targeting c-MET dysregulation, vebreltinib has demonstrated strong tumor inhibitory effect in a variety of preclinical c-MET dysregulated human gastric, hepatic, pancreatic and lung cancer xenograft animal models and patient-derived xenograft models (PDX).
Details on the Phase 1/2 SPARTA global clinical trial can be found on clinicaltrials.gov: NCT03175224. Apollomics is developing vebreltinib as single-agent cancer therapy in a variety of tumor types and actively assessing the potential of vebreltinib in combination with novel therapies. Avistone, Apollomics’ partner in China, has received conditional approval from the National Medical Products Administration (NMPA) of China for vebreltinib for multiple indications. Vebreltinib is currently under clinical investigation and not approved for any use in any other regions in the world.
About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and over 10 other countries. For more information, please visit www.apollomicsinc.com.
About LaunXP Biomedical Co., Ltd.
LaunXP Biomedical Co., Ltd. is dedicated to the development of innovative cancer therapies, including 505(b)(1) and 505(b)(2) drugs. The company’s core value lies in its focus on preclinical research and clinical trial execution.
To date, LaunXP has successfully licensed in several 505(b)(1) drug technologies, one of which has progressed to a Phase I clinical trial. In the area of 505(b)(2) drug repositioning, the company is actively pursuing new indications, including a triple-negative breast cancer drug that has completed preclinical proof-of-concept studies.
LaunXP Biomedical will continue to strengthen its R&D capabilities and is committed to becoming a driving force in the field of cancer treatment innovation.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives including with respect to the expected payments under this agreement with LaunXP and anticipated outcomes from the development and commercialization of vebreltinib with an EGFR inhibitor are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government regulations in the United States and China affecting Apollomics’ operations and the continued listing of Apollomics’ securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics’ oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv) the failure to protect Apollomics’ intellectual property; (v) breaches in data security; (vi) the risk that Apollomics may not be able to develop and maintain effective internal controls; (vii) unfavorable changes to the regulatory environment; and (viii) those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2023, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.
Investor Contacts:
Apollomics:
Eric Ribner
LifeSci Advisors, LLC
(646) 751-4363
eric@lifesciadvisors.com
LaunXP:
Chiu-Heng Chen
Chairman of the Board
(886) 4-2320-5691
john@launxp.com
FAQ
What are the financial terms of the APLM-LaunXP vebreltinib agreement?
Which territories are covered in APLM's vebreltinib development agreement?
What is the therapeutic purpose of combining vebreltinib with EGFR inhibitors?
Who will be responsible for developing vebreltinib in the licensed territory?
